Corporate Overview

Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally-recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in the USA, UK and Ireland. The Company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.

Read more

Why Invest

3

ACTIVE DRUG PROGRAMS TARGETING MAJOR DEPRESSIVE DISORDER, ALCOHOL USE DISORDER, ANXIETY DISORDERS, AND NEUROINFLAMMATION

$120M

RAISED TO DATE TO PROGRESS M&A STRATEGY AND CLINICAL TRIALS

50

NOVEL COMPOUNDS DEVELOPED WITH MORE THAN 10 PATENT FILINGS ACROSS 3 PATENT FAMILIES

$63.6M

IN CASH AND EQUIVALENTS AS OF DECEMBER 31, 2021

-->

$ in CAD

Latest News

View all news

Latest Presentation

Events and Conferences

View All Events

Latest Quarterly Reports

View All Financial Reports